The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has unveiled plans to evaluate the safety and efficacy of futibatinib (TAS-120), a potent inhibitor of the fibroblast growth factor receptor (FGFR).
The oncology research programme of NCCN provides innovation and knowledge discovery that can improve the lives of cancer patients. It also supports preclinical, clinical research and quality improvement projects in the field of oncology at member institutions of NCCN.
Under the project, NCCN will evaluate pre-clinical, translational and clinical trials using futibatinib as a monotherapy and in biologically relevant combination regimens for malignancies identified with FGFR 1-4 aberrations.
This research project will be the first NCCN programme to assess the efficacy of an FGFR inhibitor.
NCCN chief medical officer Wui-Jin Koh said: “We still have a lot to learn about FGFR signalling and how to optimally target this receptor as a component of cancer therapy. We look forward to the potential new discoveries that may come from these investigations.”
The research project is backed by $2m in funding from Japanese pharmaceutical firm Taiho Oncology.
Taiho Oncology senior vice-president and chief medical officer Martin J Birkhofer said: “We are proud to support NCCN ORP research to better understand the optimal role of futibatinib in treating malignancies with FGFR 1-4 aberrations.
“Every day, we are learning more and more about futibatinib, and this research will expand our knowledge of how this investigational compound works, with the goal of being able to better target its use in those who may see the greatest benefit from it.”
NCCN noted that the first phase of this research project will involve the RFP creation, which is expected to be distributed in the coming months.
The awarded projects under the ORP will be revealed after the review of submitted proposals.